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A B S T R A C T
The use of medicinal plants in Brazil is widespread and is supported by public 
policies; it has the objective of providing the population with safe and effective herbal 
medicines of adequate quality. An action in these policies is to develop medicinal plant 
monographs to gather published information and decide which medicinal plants should 
be financed by the Brazilian government and distributed by the public health system. 
Currently, the monographs published worldwide do not present unified information 
regarding medicinal plants, and generally, they do not cover enough requirements for 
herbal medicine registration. The aim of this study is to develop a monograph model 
with standardized information not only about botany, agronomy, quality control, safety, 
and efficacy but also about relating regulatory aspects that support herbal medicine 
regulation. The development of standardized monographs favors the fast authorization 
and distribution of herbal medicines in the public system. The model also points out 
the lacking studies that should be carried out to supplement the necessary regulatory 
information of medicinal plants.
© 2014 Sociedade Brasileira de Farmacognosia. Published by Elsevier Editora Ltda. All rights reserved.
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Introduction
Brazil is one of the countries with the largest biodiversity of 
the world; however, most of it remains unexploited (Gonçalves 
et al., 2010). Brazil is also considered to house a large number 
of researchers. Nevertheless, knowledge generated by these 
studies is generally not applied for launching new products 
to the market, resulting in few herbal medicines made of 
Brazilian medicinal plants (Carvalho et al., 2008; SBPC, 2005). 
In 2006, the Brazilian government published the National 
Policy of Integrative and Complementary Therapies, which 
includes phytotherapy in the public health system (Sistema 
Único de Saúde, SUS) (MS, 2006). In addition, in 2006, the 
National Policy of Medicinal Plants and Herbal medicines was 
published establishing the major actions to ensure the rational 
use of herbal medicines according to national legislation and 
international recommendations (Brasil, 2006).
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In 2009, the Brazilian Ministry of Health published the List of 
medicinal plants of interest for SUS (Renisus), which included 
those considered as potentially valuable for the generation 
of herbal medicines. Researchers have been encouraged to 
make use of this list as a guide to select species to study. The 
resulting information regarding the species can then be used 
to prepare the national lists of herbal medicines and medicinal 
plants, and promote development and innovation in the field 
of medicinal plants (MS, 2009).
Several monographs have been published worldwide, some 
of which are used as sources of information by many countries, 
such as the WHO Monographs on Selected Medicinal Plants 
(Veiga Junior and Mello, 2008; WHO, 1999, 2003, 2004, 2007, 
2009)
The two kinds of official monographs in Brazil are the 
Brazilian Pharmacopoeia, which includes quality control tests 
for synthetics and herbal medicines, and the Formulário de 
Fitoterápicos da Farmacopeia Brasileira, which includes safety 
of herbal formulations for pharmaceutical compounding. 
Along with these official Brazilian references, some selected 
foreign pharmacopoeias are officially used in Brazil, such as 
the United States Pharmacopoeia (USP) and USP National 
Formulary, the International Pharmacopoeia (from the World 
Health Organization - WHO), and Germanic, Argentinean, 
British, European, French, Japanese, Mexican and Portuguese 
pharmacopoeias (Anvisa, 2009b), as well as other unofficial 
monographs: Monografias de plantas medicinais brasileiras 
e aclimatadas (Gilbert et al., 2005); Farmácias Vivas (Matos, 
2000), and books including monographs of medicinal plants 
published for Brazilian phytotherapy public services. Scientific 
journals and articles are used also to gather information about 
medicinal plants. However, usually, each monograph or paper 
presents different approaches and do not face all the important 
requirements needed for a thorough documentation about 
medicinal plants, such as botanical authentication, cultivation, 
quality criteria, safety, efficacy, market, and regulatory issues 
(Veiga Junior and Mello, 2008).
Thus, a monograph template, including mandatory aspects 
as determined by Anvisa (Agência Nacional de Vigilância 
Sanitária) as well as international regulations, was developed. 
The objective is to systematize the available information on 
medicinal plants of interest to the Brazilian public health 
system.
The monograph template includes information considered 
relevant for the use of medicinal plants, based on a review of 
the scientific literature and databases to compile all previously 
published information on specific medicinal plants. This 
model’s intent is to allow for remaining non-fulfilled items in 
the monograph be used to guide future research and financing 
by the Brazilian government.
Thus, after fulfilling this model with pre-published data on 
the plant species included in the Renisus (Relação Nacional de 
Plantas Medicinais de Interesse ao SUS), it will be possible to 
identify which are the more studied medicinal plants having 
sufficient data on their safety and efficacy, to be subsequently 
financed by SUS, and gradually included in the list of herbal 
medicines with simplified registration by Anvisa (2008a). 
The products included in this list must follow a strict set of 
standardization so the registration process is easier and faster 
than usual registration. For the less studied medicinal plants 
it would be possible to indicate which studies are needed to 
validate its use.
The monograph template presented herein is intended to be 
used by researchers funded by the Brazilian Ministry of Health 
to evaluate the plant species included in the Renisus. Following 
their completion, monographs will be reviewed by experts in 
the areas of interest and will be initially published as a public 
consultation to allow all stakeholders to contribute to the final 
monograph. It is also envisaged that the monograph template 
will guide the research and inclusion of important information 
for the publication of medicinal plant data. Thus, articles and 
books published under this model may be quickly recognized 
by Anvisa, among their reference lists, for evidence of safety, 
efficacy, and quality of herbal medicines.
Material and methods 
Building the template
To support the template proposal, a comparative and 
exploratory study was performed by a comparison and 
consideration of the set of information presented in the 
monographs listed by Anvisa Normative Instruction 05/10 
(Anvisa, 2010e): WHO Monographs on selected medicinal 
plants, tomes 1-4 (WHO, 1999, 2004, 2007, 2009); European 
scientific cooperative on phytotherapy - Monographs on 
the medicinal uses of plant drugs (ESCOP, 1996); American 
Herbal Pharmacopoeia (Upton and Petrone, 1999); Monografias 
de plantas medicinais brasileiras e aclimatadas (Gilbert et al., 
2005), British Herbal Compendium (Bradley, 2006); Expanded 
Commission E monographs (Blumenthal, 1999; Blumenthal 
et al., 2000); and Vademécum nacional de plantas medicinales 
(Cáceres, 2006). This data is available at Carvalho, 2011.
The next step was the evaluation of regulation requirements 
for herbal medicine registration and for plant notification at 
Anvisa, as well as requirements on regulations for herbal 
medicines from other agencies such as: European Medicines 
Agency (EMA), Health Canada (HC-SC), Comisión Federal para 
la Protección contra Riesgos Sanitarios (Cofepris), Administración 
Nacional de Medicamentos, Alimentos y Tecnología Médica 
(ANMAT), and the Paraguayan Health Ministry (Anmat, 1998, 
1999a, b; Cofepris, 1998a, b, 2000, 2001, 2006, 2013; EMA, 2006a, 
b, c, d, 2007, 2008a, b, 2010a, b, c, d; HC-SC, 2003, 2006, 2007, 
2010a, b; Paraguai, 1997). A preliminary template was created 
to verify if all the requirements were present, after which 
the template was submitted to peer review evaluation of the 
members of the Anvisa Herbal Medicine Technical Chamber 
(CATEF) and the Support Committee of Medicinal Plants and 
Herbal Medicines Policy from Brazilian Pharmacopoeia (CTT-
APF) (Anvisa, 2010b; CATEF, 2010). The new template, with 
the reviewer-suggested modifications included, was tested at 
the preparation of the Maytenus officinalis Mabb., Celastraceae, 
monograph (unpublished results). 
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Results and discussion 
The template
The proposed template is divided into seven main sections, 
namely: general information, pharmacognostic authentication, 
agronomical information, quality control, safety and efficacy, 
other information and references.
General information
This section must include all accepted names and basic 
information about the plant species, including vernacular 
name, scientific name, all known synonyms, images, and 
geographic distribution. Geographic distribution is important 
considering eventual financial support because Brazilian native 
species should be prioritized (Brasil, 2006).
Several useful free databases, such as “The plant list” 
and Lista de espécies Flora do Brasil can be accessed to ensure 
accuracy of the information. Lista de espécies Flora do Brasil 
database includes information on over 40,000 Brazilian species 
(JBRJ, 2012; MBG, 2013). 
Pharmacognostic authentication
This section refers to plant parts or organs used as raw 
materials in herbal medicine production and should be as 
complete as possible to allow correct species identification. 
This information is usually found in pharmacopoeias. In 
Addition, Brazilian Pharmacopoeia presents figures showing 
the macro and microscopic characteristics from particularly 
useful herbal drugs (Anvisa, 2010a; Veiga Junior and Mello, 
2008). Furthermore, this section should present information 
about all known species that could be used for counterfeit 
or misidentification, an important point for quality control. 
Data on other species used in folk medicine misidentified as 
the same plant or vernacularly named as the described plant 
species should be informed, particularly for native species. 
This information is valuable considering that in Brazil it is not 
rare that different species share the same vernacular name. 
Nevertheless, according to Brazilian regulation, to register a 
herbal medicine a complete dossier for the specific medicinal 
plant is mandatory, and all others species not presented at 
the dossier are considered as contamination (Anvisa, 2010a, 
b; Veiga Junior and Mello, 2008).
It is important to check for already collected and published 
data, which should also follow best practices, in this case, 
related to Botany. There are recommendations for collecting 
and cataloguing specimens, in relation to sustainability issues, 
as there are particular specifications for collecting, drying, and 
preparing of herbarium specimens (WHO/IUCN/WWF, 1993). 
Thus, if there is documentation regarding gathering and 
recording of vouchers specimens, this information should be 
included in the monograph.
Agronomical information 
This section aids the implementation of the Good Agricultural 
Practices the first step in herbal medicine manufacture. This 
section should include data concerning the biology, phenology, 
production system, cultivation method, processing, storage, 
and seed characteristics (Scheffer et al., 2006).
Furthermore, this section’s data can help define strategies 
to improve the culture of target species to achieve better yields 
of selected phytopharmaceuticals. Agricultural practices can 
directly affect the quality of herbal medicines. International 
guidelines (e.g. WHO) can be used, given the lack of specific 
regulations in Brazil (Scheffer et al., 2006; WHO, 2003).
Agronomical information in this section enables the 
collection of data to assist projects for the standardized, 
homogeneous, and continuous production of plant materials; 
as well as the reproduction and genetic preservation of species 
of interest and biodiversity conservation. Information on 
the influence of seasonality over raw material productivity, 
active compound yield, and toxicity is important, as well as 
phytosociology, ecology, successional groups, and threat of 
extinction should be included.
Other crucial activities that should be controlled, such 
as soil analysis, pesticide contamination control, and water 
quality for irrigation to avoid plant drug pollution, should 
be described. Crop techniques and phytosanitary issues 
determine plant development and, consequently, the 
productivity and active compound yield (Scheffer et al., 2006; 
WHO, 2003). Much standardized agronomy information may 
not have yet been established for the medicinal plant described 
at the monograph, particularly when the plant is obtained by 
extractivism (wildcrafting). Thus, the item must be completed 
with the information “the requested data has not yet been 
published”.
Quality control
Concerning Brazilian regulation, the requirements for the 
quality control of herbal medicines are defined by RDC 14/10 
(Anvisa, 2010e), and those related to pharmaceutical stability 
and analytical method validation are defined by RE 01/05 
and 899/03 (Anvisa, 2003, 2005). For notifiable plants (herbal 
drugs traditionally chosen for simplified sales authorization), 
the quality control requirements are specified by RDC 10/10 
(Anvisa, 2010c).
For herbal medicines, controls should be performed at all 
production steps, including the raw materials, which may be 
herbal drugs or herbal preparations, and the final product, the 
herbal medicine. All available published information on these 
tests and specifications standardized for the medicinal plant 
must be included in the monograph.
For the herbal drug, information about specifications on 
granulometry/particle size, organoleptic properties, presence 
of foreign materials such as ash, moisture, microscopic 
and macroscopic contaminants including fungi, bacteria, 
mycotoxins and heavy metals, should be given. Finally, 
qualitative and quantitative markers should be listed (Anvisa, 
2010b).
For the herbal preparation, the extraction methods and the 
possibility of residual solvent presence must be included. For 
the final product, the control varies according to the dosage 
form, but it must guarantee the integrity and stability of the 
product, as well as the control level of microbial contamination 
(Anvisa, 2010d). Possible contaminants and the tests for 
identification and quantification of markers should be included 
 Ana C. B. Carvalho et al. / Rev Bras Farmacogn 24(2014): 80-88 83
in the following three stages: herbal drug, herbal preparation, 
and the herbal medicine itself (Anvisa, 2010e). 
In general, the official pharmacopoeias must be used to 
complete this section. The Brazilian Pharmacopoeia, 5th Ed. 
presents sixty monographs on medicinal plants and plant 
preparations. From these, only twelve refer to medicinal 
plants listed by Renisus. In the General Procedures section 
or in specific plant monographs of Brazilian Pharmacopoeia, 
protocols can be found for identification, microbiological 
control, ash content, humidity, and marker compound limits 
(Anvisa, 2010a). 
Brazilian legislation prohibits the use of pesticides 
in medicinal plant crops. However, as this practice is 
allowed in several countries, and considering that Brazilian 
pharmaceutical companies can import the herbal raw 
materials, the presence of these substances must be stated. 
Therefore, all available information on pesticide limits for the 
medicinal plant should be included. 
Any data available in the scientific literature regarding the 
best analytical techniques and specifications applied to each 
species, such as the use of thin-layer chromatography or high 
performance liquid chromatography for identification tests, 
should be stated.
Safety and efficacy
To register herbal medicines in Brazil, as done by the European 
community, pharmaceutical companies may present data on 
traditional use or non-clinical and clinical studies.
Information about traditional use
This section of the monograph should include information 
on the traditional use of the plant species, which, according 
to Brazilian law, must be demonstrated for a period of at 
least 20 years (long-term safe use), without serious adverse 
reports. Also, it should include studies demonstrating that 
the medicinal plant or herbal medicine does not contain toxic 
constituents. 
Information about nonclinical and clinical assays
In agreement to Brazilian legislation, if there is not enough data 
on the traditional use of the medicinal plant, it is necessary to 
present data on non-clinical and clinical studies, which can be 
previously published. Only if enough data is not available, it 
will need to be tested by the company that intends to register 
the product. Considering this information, this section should 
include data on pharmacological and toxicological assays, 
separated by non-clinical and clinical studies (Anvisa, 2004, 
2008b, 2010e; CNS, 1996, 1997). This structure was designed to 
present a panoramic view of the species and its derivatives, 
enabling detection of the most studied derivatives. However, 
many of the plants do not have complete clinical study data; 
subsequently, after reviewing the published literature and 
completing the monograph, it will be easy to find which 
species studies still require research and, thus, financing.
Data should be organized in a systematic way, such as by 
part of plant, derivative, chemical composition of the extract, 
tested doses, methodology, models, results, and references. 
Non-clinical toxicology data should be divided into acute 
toxicity, sub-chronic, and chronic tests. According to Brazilian 
RE 90/04, information regarding mutagenicity, genotoxicity, 
dermic sensibility, and cutaneous and ocular irritation should 
also be informed (Anvisa, 2004).
In accordance to RDC 47/09 or RDC 10/10, this section should 
also include information regarding route of administration, 
daily doses, posology, adverse effects, contraindications, risk 
groups, time limits for usage, precautions, interactions, and 
overdose effects (Anvisa, 2009a, 2010c).
Other information
Finally, the proposed template also presents a section on 
pharmaceutical form and formulation. Patent information 
can easily be found online at webpages such as Instituto 
Nacional de Propriedade Industrial, World International Property 
Organization, European Patent Office and Japan Patent 
Information Organization (EPO, 2011; INPI, 2011; JAPIO, 2011; 
WIPO, 2011). This information is important for the Ministry 
of Health, since it is preferable to finance research on non-
patented extracts that can be produced at more affordable 
prices.
Other information should be included, if available in the 
scientific literature, such as special packaging, labeling, storage, 
and transportation (e.g., if the product must be protected from 
light). In addition, all known official or unofficial published 
monographs worldwide on the specific medicinal plant, 
including data regarding quality control, safety, and efficacy 
must be stated. Information about the regulatory conditions in 
other countries and licensing by Anvisa and/or other regulatory 
agencies, as obtained through official reports or publications, 
is also required. This information is important because this 
data shows that the medicinal plant has been evaluated and 
that its use in other countries was allowed, helping confirm 
its safety and effectiveness. Regulations of ANMAT, EMA, and 
HC-SC usually consider an existent herbal medicine register 
as a positive item in the registration process.
In Brazil, the extensive number of product registrations for 
the same species will favor its inclusion among those financed 
by SUS.
References
This section presents a Chart containing all scientific references 
used to elaborate the monograph on the medicinal plant used, 
including the category of the information (Pharmacology, 
Agronomy etc.). 
The suggested referencing style is Vancouver. The scientific 
information required to complete the monograph can be found 
at PubMed, Lilacs, Napralert, Science Direct, CAPES thesis, 
Scifinder, Micromedex, Scopus, Biological Abstracts, Medscape, 
Toxnet, and other databases.
Conclusions
A review of published studies/information on each 
medicinal plant of interest to the Brazilian government 
according to the developed template should provide 
complete information on each medicinal plant. Information 
obtained in the monograph will help for the evaluation of 
available information on a specific plant species and the 
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necessary effort to complete any missing information. 
Such evaluation is important in the decision-making 
process for the funding of further studies on the quality, 
efficacy, and safety of medicinal plants. The scientific 
data on the monograph must be constantly re-evaluated 
and the monograph needs to be re-published, so that 
the new information available in the scientific literature 
can be updated. The suggested period for review of each 
monograph is each year, based on our experience with 
M. ilicifolia monograph (unpublished data): an evaluation 
showed that one year after the elaboration of the monograph, 
several scientific studies had already been published.
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1. General information
1.1. Latin name
1.2. Synonyms
1.3. Family
1.4. Image of the plant
1.5. Popular names
1.6. Geographical distribution
2. Botanical authentication
2.1. Part used/organ types
2.2. Macroscopic description
2.3. Microscopic description
2.4. Information on similar plant species 
  that can be used as adulterants
2.5. Information on voucher specimens
3. Agronomic information
3.1 Biology and phenology 
3.1.1. Sexual system
3.1.2. Flowering time
3.1.3. Fruiting period
3.2. Form of fruit and seed dispersal
3.3. Production system
3.3.1. Information on seeds
3.3.2. Harvesting and processing
3.3.3. Seed weight (by mg/1,000 seeds)
3.3.4. Productivity
3.3.5. Dormancy of seeds
3.3.6. Longevity and storage
3.4. Germination
3.4.1. Information on crop
3.4.2. Description
3.4.3. Propagation
3.4.4. Growth and production
3.4.5. Characteristics of the soil
3.4.6. Climatic characteristics
3.4.7. Time of collection/harvesting
3.4.8. Habit and regeneration
3.4.9. Consortium
3.4.10. Agroforestry system
3.4.11. Breeding
3.4.12. Pests and diseases (occurrence, level of 
 damage and control)
3.5. Processing information
3.5.1. Drying
3.5.2. Processing
3.5.3. Expected return
3.5.4. Packing
3.6. Storage information
3.7. Information on seasonal variation of markers
3.8. Information about whether the management 
  affects markers
3.9. Ecological aspects
4. Quality control information (to be completed for plant species, 
plant preparations, and the final product - the herbal medicine). 
Chart 1: Information about quality control
 Herbal drug Herbal preparation Herbal medicine
 Granulometry/
 particle size 
Description Dosage forms
 - Methods of production Specific tests for each 
    pharmaceutical form
 - Physycochemical tests -
      Organoleptic characteristics -
 Purity requirements
  Microbiological testes
  Humidity
  Heavy metals
  Chemical residues
  Ashes
         Phytochemical analysis
           Identification test
Quantification tests (Chemical constituents and concentrations):
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Markers or active compounds
Other considerations related to quality control
5. Safety and efficacy information
5.1. Information on traditional use
5.2. Information about nonclinical and clinical assays
5.2.1. Nonclinical toxicology
5.2.1.1. Subcronic
5.2.1.2. Cronic
5.2.1.3. Genotoxicity
5.2.1.4. Dermic sensibilization
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  derivatives
5.4. Routes of administration
5.5. Daily dose
5.6. Posology
5.7. Period of use
5.8. Contraindications
5.9. Risk groups
5.10. Warnings
5.11. Adverse effects
5.12. Drug interactions
5.12.1. Described
5.12.2. Potential
5.13.  Overdose information
5.13.1. Description of the clinical situation
5.13.2. Actions to be taken
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7. List of references
Chart 2: References
 No Author and title Year Knowledge area Reference
6. Other information
6.1. Dosage forms/formulations described in the literature
6.2. Products registered at Anvisa and other regulatory
  agencies
6.3. Packaging and labeling information
6.4. Monographs about the medicinal plant in oficial and
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6.5. Patents applied for the plant species
6.6. Curiosities
